192 related articles for article (PubMed ID: 23319766)
1. Mechanisms of resistance to PARP inhibitors--three and counting.
Fojo T; Bates S
Cancer Discov; 2013 Jan; 3(1):20-3. PubMed ID: 23319766
[TBL] [Abstract][Full Text] [Related]
2. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors in cancer: moving beyond BRCA.
Telli ML
Lancet Oncol; 2011 Sep; 12(9):827-8. PubMed ID: 21862406
[No Abstract] [Full Text] [Related]
4. Molecular stratification and repair defects: revealing hidden treasures.
Hutchinson L
Nat Rev Clin Oncol; 2015 Dec; 12(12):683. PubMed ID: 26573421
[No Abstract] [Full Text] [Related]
5. Third of men with treatment resistant prostate cancer respond to drug that targets gene defect, study finds.
Mayor S
BMJ; 2015 Oct; 351():h5783. PubMed ID: 26518710
[No Abstract] [Full Text] [Related]
6. Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer.
Chedgy EC; Black PC
Urology; 2016 Mar; 89():10-1. PubMed ID: 26723184
[No Abstract] [Full Text] [Related]
7. [Research progresses of the PARP inhibitors for the treatment of cancer].
He YJ; Liu RH; Ning CQ; Yu NF
Yao Xue Xue Bao; 2013 May; 48(5):655-60. PubMed ID: 23888686
[TBL] [Abstract][Full Text] [Related]
8. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
Lord CJ; Ashworth A
Nat Med; 2013 Nov; 19(11):1381-8. PubMed ID: 24202391
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors for chemoprevention--reply.
To C; Sporn MB; Liby KT
Cancer Prev Res (Phila); 2014 Nov; 7(11):1172. PubMed ID: 25368012
[No Abstract] [Full Text] [Related]
11. PARP inhibitors for chemoprevention--letter.
Chand SN; Blanco FF; Jimbo M; Tsangaris TN; Cristofanilli M; Yeo CJ; Winter JM; Pishvaian MJ; Brody JR
Cancer Prev Res (Phila); 2014 Nov; 7(11):1170-1. PubMed ID: 25368011
[No Abstract] [Full Text] [Related]
12. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
14. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
15. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
[TBL] [Abstract][Full Text] [Related]
16. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
17. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Delaye M; Rodrigues M
Bull Cancer; 2021 Apr; 108(4):350-351. PubMed ID: 33641880
[No Abstract] [Full Text] [Related]
18. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
19. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
20. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
